Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Description

The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Conditions

Inflammation

Talk to us

Study Overview

On this page

Study Details

Study overview

The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation

Condition
Inflammation
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age: ≥18
  • 2. Patient has no prior history or current use of Sodium-Glucose Co-transporter 2 Inhibitors.
  • 3. Women who are surgically sterilized, amenorrheic for a year, on long-term contraceptives like intrauterine devices, Implantable, and injectable contraceptives.
  • 4. Willing and able to complete the outcome assessments.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Study Record Dates

2026-06